Raymond P. Warrell, M.D.
Founder, Chief Executive Officer, and Member of the Board
Inventor of the Relburn drug prototype, Ray has more than 25 years of achievement in scientific research, clinical development, finance, operations, regulatory and legal affairs, and senior executive business management experience in the pharmaceutical, diagnostic, and biotechnology sectors.
Ray was the lead inventor of two earlier drugs, drafted their INDs, secured their designations as “Orphan Drugs”, and designed and led the Phase 1-3 clinical trials that were pivotal for FDA approval. These drugs were acquired by Fujisawa (Astellas) and Cell Therapeutics Inc., respectively, for investor exits of $650 million and $275 million. For this work, he received FDA’s Public Health Service Award for “Exceptional Achievement in Orphan Drug Development”.
Ray was Chief Executive Officer and Chairman of Genta Incorporated (Nasdaq: GNTA), a biotechnology company focused on mRNA regulation of cancer cell apoptosis. Previously, he served as Associate Physician-in-Chief and Member at Memorial Sloan-Kettering Cancer Center in New York, and Professor of Medicine at the Weill Cornell University Medical College. He received a B.S (Chemistry) from Emory University, a M.D. from the Medical College of Georgia, and a M.B.A. from Columbia University.
John J. Piwinski, PhD
Head of Drug Discovery and Nonclinical Research
As a senior medicinal chemist, John has over 30 years of experience in running drug discovery programs from project initiation to delivery of clinical candidates.
At Schering-Plough and Merck, John was most recently Site Head and Group Vice-President of Merck’s Cambridge, MA site, which focused on medicinal chemistry (lead identification and optimization), affinity-based screening, bio-nuclear magnetic resonance (screening and structure-based drug design), protein science, and biologics. Previously, as Group Vice President, he oversaw Chemical Research at Schering’s Kenilworth, NJ facility with broad experience in immunology, cardiovascular, CNS, oncology and infectious disease. Prior to joining Schering Plough, he was a Senior Scientist at Revlon Health Care in cardiovascular diseases. He is a Principal of JJPiwinski Pharma Consulting, LLC, Lebanon, NJ – a firm that specializes in medicinal chemistry and drug discovery.
John received a B.S. (Chemistry/Biochemistry) from SUNY-Stony Brook and a Ph.D. in Organic Chemistry from Yale University. He currently serves on an NIH Drug Development Program Review Panel and is a member of the Advisory Board for the Institute of Chemical Biology & Drug Discovery at Stony Brook.